WO2021007636A1 - Estereoisômeros do composto 3-(benzo[d][1,3]dioxol-5-il)-7-(1-hidroxipropan-2-il)-1-(1 h-indol-3-il)-6,7-dihidro-3 h-oxazol[3,4-a]pirazina-5,8-diona e seu uso como antitumoral e inibidor da enzima fosfodiesterase - Google Patents
Estereoisômeros do composto 3-(benzo[d][1,3]dioxol-5-il)-7-(1-hidroxipropan-2-il)-1-(1 h-indol-3-il)-6,7-dihidro-3 h-oxazol[3,4-a]pirazina-5,8-diona e seu uso como antitumoral e inibidor da enzima fosfodiesterase Download PDFInfo
- Publication number
- WO2021007636A1 WO2021007636A1 PCT/BR2020/050259 BR2020050259W WO2021007636A1 WO 2021007636 A1 WO2021007636 A1 WO 2021007636A1 BR 2020050259 W BR2020050259 W BR 2020050259W WO 2021007636 A1 WO2021007636 A1 WO 2021007636A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dioxol
- benzo
- dihydro
- pyrazine
- dione
- Prior art date
Links
- WBDAVQYSTVSHHJ-YEBMWUKDSA-N C[C@H](CO)N(CC(N1C2=C(c3c[nH]c4ccccc34)O[C@@H]1c(cc1)cc3c1OCO3)=O)C2=O Chemical compound C[C@H](CO)N(CC(N1C2=C(c3c[nH]c4ccccc34)O[C@@H]1c(cc1)cc3c1OCO3)=O)C2=O WBDAVQYSTVSHHJ-YEBMWUKDSA-N 0.000 description 3
- WBDAVQYSTVSHHJ-OZAJXLCCSA-N C[C@H](CO)N(CC(N1C2=C(c3c[nH]c4ccccc34)O[C@H]1c(cc1)cc3c1OCO3)=O)C2=O Chemical compound C[C@H](CO)N(CC(N1C2=C(c3c[nH]c4ccccc34)O[C@H]1c(cc1)cc3c1OCO3)=O)C2=O WBDAVQYSTVSHHJ-OZAJXLCCSA-N 0.000 description 3
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Definitions
- the present patent application relates, in a first aspect, to phosphodiesterase (PDE) inhibitor compounds.
- PDE phosphodiesterase
- the present patent application relates, in a second aspect, to antiproliferative and anti-tumor compounds.
- Such compounds can be used, for example, as anti-inflammatories, vasodilators, stimulants and inotropes in heart failure and lung diseases.
- PDE inhibitors have been shown to be useful in the treatment of erectile dysfunction in men.
- such compounds can be used as antiproliferative and anti-tumor agents.
- Phosphodiesterase inhibiting compounds are the main agents used in medical practice for the treatment and / or prevention of erectile dysfunction, disorders and / or conditions treatable with tissue relaxation and other diseases treatable with phosphodiesterase inhibitors. In the case of erectile dysfunction, PDE-5 inhibitors are the most used in medical practice.
- Erectile dysfunction more commonly known as sexual impotence is one of the diseases that most impairs a man's quality of life. For a long time, erectile dysfunction haunted men without much possibility of effective treatment.
- cGMP-PDE inhibitors More specifically PDE-5 inhibitors.
- the precursor of these compounds was 5- [2-ethoxy-5- (4-methylpiperazinylsulfonyl) phenyl] -1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo [4, 3-d] pyrimidine -7-one, or sildenafil, with vasodilating properties and which potentiates the effects of nitric oxide.
- the sildenafil molecule was originally described in US patent US5250534.
- tissue relaxing compounds have been used to promote relaxation of various tissues with a focus on treating or acting as an adjunct to treatment, procedure or surgery related to lithiasis (Korkes, F. et al, J Bras Nefrol. (2009) 31 (1): 55), prostate enlargement (eg, benign prostatic hyperplasia, prostatitis) (WO 9911279) and urethral constriction (Van der wasf et al, BJU International (2002) 90: 588).
- Other treatable disorders and / or conditions of tissue relaxation are known and described in the prior art.
- the compounds now claimed are placed as alternatives for the treatment of various diseases and medical conditions that benefit from PDE inhibition, such as erectile dysfunction, heart failure, pulmonary hypertension and for the treatment of various diseases and conditions that benefit from its antiproliferative and anti-tumor effects.
- the present patent application relates, in one aspect, to the compound 3- (benzo [d] [1, 3] dioxol-5-yl) -7- (1-hydroxypropan-2-yl) -1- (1H- indol-3-yl) - 6,7-dihydro-3H-oxazol [3,4-a] pyrazine-5,8-dione of formula (I), and its stereoisomers,
- said stereoisomers of the compound of formula (I) are in their separate individual forms and / or in the forms of racemic mixtures or mixtures non-racemic with diastereoisomeric excess in any proportions.
- stereoisomers are the compounds of formulas (II) and (III)
- the present patent application relates to the isolated stereoisomers named by the formulas (IV), (V), (VI) and (VII), below:
- Another aspect of the present patent application relates to mixtures of stereoisomers of compound 3-
- the present patent application seeks protection for non-racemic mixtures with diastereoisomeric excess in any proportions.
- the diastereoisomeric ratio is in the range of 1:99 to 99: 1.
- the mixture is in the range of 1:50 to 50: 1, alternatively in the range of 1:25 to 25: 1.
- mixtures non-racemic with diastereoisomeric excess are in the range of 1: 2 to 2: 1, alternatively in the proportion of 1: 1.
- the present patent application relates to the mixture of diastereoisomers described in formulas (VIII) and (IX), the mixture being able to contain any proportion of the diastereoisomers.
- the diastereoisomeric ratio is in the range of 1:99 to 99: 1.
- the mixture is in the range of 1:50 to 50: 1, more preferable in the range of 1:25 to 25: 1.
- the mixture is in the range of 1: 2 to 2: 1, more preferred in the proportion of 1: 1.
- the mixture of diastereoisomers of formula (IX) is called (R) -3- (benzo [d] [1, 3] dioxol-5-yl) -7- ((S) -1- hydroxypropan-2-yl) - 1- (1H-indol-3-yl) -6,7-dihydro-3H-oxazole [3,4-a] pyrazine-5,8-dione with (S) -3- (benzo [d] [1, 3] dioxol-5-yl) -7- ((S) -1-hydroxypropan-2-yl) -1- (1H-indo1-3-yl) - 6,7-dihydro-3H-oxazole [3,4 -a] pyrazine-5, 8-dione (BL-241), and has the following structure: BL-241
- the diastereoisomeric ratio is in the range of 1:99 to 99: 1.
- the mixture is in the range of 1:50 to 50: 1, alternatively in the range of 1:25 to 25: 1.
- the mixture is in the range of 1: 2 to 2: 1, alternatively in the proportion of 1: 1.
- Diastereoisomers and their mixtures, objects of the present patent application can be prepared, for example, according to the reaction schemes below:
- compositions comprising said stereoisomers of the compound of formula (I) in their separate individual forms and / or in the forms of racemic mixtures or non-racemic mixtures with excess stereoisomers in any proportions and medicaments comprising said stereoisomers.
- Such compositions can be prepared according to known methods of pharmaceutical technology, using pharmaceutically acceptable diluents, excipients or carriers.
- Another aspect of the present patent application is the use of the compound of formula (I) and its stereoisomers as antitumor and inhibitors of the phosphodiesterase enzyme, more specifically as antitumor and inhibitors of the type 5 phosphodiesterase enzyme (PDE-5); and the use of said stereoisomers in the treatment of benign prostatic hyperplasia and cancer, more specifically prostate cancer.
- PDE-5 type 5 phosphodiesterase enzyme
- a preferred aspect of the present patent application concerns the use of the mixture defined by formula (VIII) and named as (R) -3- (benzo [d] [1, 3] dioxol-5-yl) -7- ( (R) -1- hydroxypropan-2-yl) -1- (1H-indol-3-yl) -6,7-dihydro-3H-oxazol [3,4-a] pyrazine-5,8-dione with ( S) -3-
- Another preferred aspect of the present patent application concerns the use of isolated stereoisomers defined by formulas (IV), (V), (VI) and (VII) and named, respectively, as: (S) -3- (benzo [ d] [1, 3] dioxol-5-yl) -7-
- Also used in the present patent application are the uses of the compound of formula (I) and its stereoisomers, salts, esters, prodrugs, as described herein, in the preparation of antiproliferative, anti-tumor and anti-tumor drugs phosphodiesterase enzyme, more specifically phosphodiesterase type 5 (PDE-5) inhibitors; and the use of said stereoisomers in the preparation of medications for the treatment of diseases and conditions, such as inflammatory, cardiovascular, pulmonary diseases and conditions, erectile dysfunction in men, benign prostatic hyperplasia and cancer, more specifically prostate cancer.
- diseases and conditions such as inflammatory, cardiovascular, pulmonary diseases and conditions, erectile dysfunction in men, benign prostatic hyperplasia and cancer, more specifically prostate cancer.
- the present patent application also describes a method of treating cancer, such as benign prostatic hyperplasia and cancer, more specifically prostate cancer, using the stereoisomers of the compound of formula (I), its salts, solvates, hydrates, prodrugs and pharmaceutically acceptable esters; where stereoisomers are in their separate individual forms and / or in the forms of racemic mixtures or non-racemic mixtures with diastereoisomeric excess in any proportions.
- cancer such as benign prostatic hyperplasia and cancer, more specifically prostate cancer
- Such uses and treatment methods described above include providing a therapeutically effective amount of the compounds, and their respective salts, solvates, prodrugs, stereoisomers and racemic mixtures thereof.
- Another object of the present patent application is the process of producing the stereoisomers of compound 3- (benzo [d] [1,3] dioxol-5-yl) -7- (1-hydroxypropan-2-yl) -1- ( 1H-indol-3-yl) -6,7-dihydro-3H-oxazol [3,4-a] pyrazine-5,8-dione of formula (I), as described in the above schemes and examples below.
- Example 1 Preparation of the Compound of formula (VI II)
- the intermediate compound (E) -methyl 2- ((benzo [d] [1, 3] dioxol-5-yl methylene) amino was added to a 500 mL flask with mechanical stirring, addition funnel and drying tube containing CaCl2 ) -3- (1H-indol-3-yl) -3-oxopropanoate of formula (A) (5.0 g, 13.7 mmol), dry THF (90 ml) and dry pyridine (5.5 ml) which was stirred for 30 minutes.
- the flask was cooled to room temperature and subsequently between 0 and 5 ° C, and stirred for 2 h at this temperature.
- the solid was placed in a 100 ml flask and 30 ml of ethanol was added; the mixture was stirred for a period of 30 minutes. After this period, the solid was filtered and dried under vacuum, leading to the formation of the compound of formula (VIII), constituted by the mixture of the corresponding compounds (VI) and (VII) in 41% yield.
- the compound obtained by this process has IUPAC nomenclature (R) -3- (benzo [d] [1, 3] dioxol-5-yl) -7- ((R) -1- hydroxypropan-2-yl) -1- (1H-indol-3-yl) -6,7-dihydro-3H-oxazole [3,4-a] pyrazine-5,8-dione with (S) -3-
- reaction intermediates the following compounds were used: (E) -methyl 2- ((benzo [d] [1, 3] dioxol-5-yl methylene) amino) -3- (1H-indol-3-yl) -3- oxopropanoate, described by the chemical structure (A); compound (R) -2-aminopropane-1-ol (3), and 2-chloroacetyl chloride (1), as exemplified below and in scheme 1.
- the compound obtained by this process has IUPAC nomenclature (R) -3- (benzo [d] [1, 3] dioxol-5-yl) -7- ((S) -1- hydroxypropan-2-yl) -1- (1H-indol-3-yl) -6,7-dihydro-3H-oxazole [3,4-a] pyrazine-5,8-dione with (S) -3-
- reaction intermediates the following compounds were used: (E) -methyl 2- ((benzo [d] [1, 3] dioxol-5-yl methylene) amino) -3- (1H-indol-3-yl) -3- oxopropanoate, described by the chemical structure (A); and compound (S) -2-aminopropane-1-ol (4) and chloroacetyl chloride (1), as exemplified below and in scheme 2.
- the mother water from the previous filtration was returned to the reaction flask and 200 mL of H2O was added slowly, leading to a turbidity of the reaction medium, which was stirred for 1 hour at room temperature.
- the suspension was filtered in vacuo and washed with 50 ml of ethanol.
- Example 7 In vitro evaluation of the inhibitory potential of compounds under the activity of the human phosphosdiesterase 5 enzyme.
- the evaluation of the compound is studied using an enzymatic assay kit from BPS Bioscience (catalog 60350).
- the PDE5A1 assay kit allows identification of PDE5A1 inhibitors using fluorescence polarization.
- the assay is based on the binding of a fluorescent nucleotide monophosphate generated by the PDE5A1 enzyme to the binding agent.
- test compounds are diluted with 100% DMSO (v / v) to a concentration of 1000 mM and then diluted in 0.9% sodium chloride solution to obtain the concentration curve of interest for the test.
- the compounds are diluted in concentrations of: 10 nM, 30 nM, 50 nM, 100 nM, 300 nM, 500 nM, 1 mM, 3 mM, 5 mM (10% v / v DMSO).
- the study is composed of the groups: (i) substrate control; (ii) positive control (KIT); (iii) samples in various concentrations; (iv) tadalafil (comparative control). Each parameter (group) is plated in triplicate.
- the reaction is stopped by adding 100 ml of the binding agent solution to all wells and the microplate is incubated for 30 minutes, under gentle agitation, at room temperature.
- the microplate reading is performed in Polarized Fluorescence (475-495 nm - excitation and 518-538 nm - emission detection) 500 nanoseconds of integration time.
- concentrations of 10 nM, 30 nM, 50 nM, 100 nM, 300 nM, 500 nM, 1 mM (1000 nM), 3 mM (3000 nM) and 5 mM (5000 nM) were prepared. Based on the results obtained (Table 1) it is possible to observe that the compound BL-380 was effective in inhibiting PDE5 in a dose dependent manner, however this inhibition was only observed from the concentration of 300 nM of BL-380.
- BL-241 compound concentrations of 500 nM, 1 mM (1000 nM) and 3 mM (3000 nM) were prepared. Based on the results obtained, (table 2) it is possible to observe that the compound BL-241 was also effective in inhibiting PDE5 in a dose dependent manner.
- Example 6 Evaluation of the antiproliferative effect of compounds in cell cultures of human prostate, stomach and bladder cancer lineages.
- the compounds are diluted in 100% DMSO (v / v) to a concentration of 1000 mM and then diluted in 0.9% sodium chloride solution to obtain the stock solutions of interest for use in the tests.
- the final concentration of interest will be diluted directly in the cell culture medium.
- the following tumor cell lines are used for the experiment: PC3-human prostate cancer; LNCAP- human prostate cancer; DU145-human prostate cancer; MNK45-human stomach cancer and RT4-human bladder cancer.
- Tumor cell lines are maintained in culture according to standard procedures established by the Rio de Janeiro Cell Bank (place of origin of the lines). Procedure:
- tumor cells are seeded at a concentration of 10,000 cells per well (final reaction volume 200. Ml), the plate is incubated for 8 hours so that the cells adhere to the wall of the wells. After this period, the plaque is divided into groups:
- test group added 20 mL of samples (test compound) at the concentrations of interest;
- negative control group added 200 ml of culture medium and 20 ml of the vehicle used to dilute the compounds (without cells - zero proliferation);
- control group added 20 mL of the vehicle used to dilute the compounds. This group is important for assessing whether the vehicle used interferes with cell proliferation.
- the treatment with the concentrations of the samples (test compounds) and controls are carried out in triplicate.
- stock solutions are prepared in the concentrations of: 100 nM, 1 mM, 3 mM, 5 mM, 10 mM and 30 mM (DMSO 10% v / v).
- the final concentrations in the test are: 10 nM, 100 nM, 300 nM, 500 nM, 1000 nM and 3000 nM (in DMSO 1% v / v).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112021024894A BR112021024894A2 (pt) | 2019-07-15 | 2020-07-14 | Estereoisômeros do composto 3-(benzo[d][1,3]dioxol-5-il)-7-(1-hidroxipropan-2-il)-1-(1h-indol-3-il)-6,7-dihidro-3h-oxazol[3,4-a]pirazina-5,8-diona e seu uso como antitumoral e inibidor da enzima fosfodiesterase |
KR1020217043172A KR20220035048A (ko) | 2019-07-15 | 2020-07-14 | 화합물 3-(벤조[d][1,3]디옥솔-5-일)-7-(1-하이드록시프로판-2-일)-1-(1H-인돌-3-일)-6,7-디하이드로-3H-옥사졸[3,4-a]피라진-5,8-디온의 입체이성질체 및 항종양제 및 포스포디에스테라제 효소 억제제로서의 이의 용도 |
MX2021015425A MX2021015425A (es) | 2019-07-15 | 2020-07-14 | Estereoisomeros del compuesto 3-(benzo[d][1,3]dioxol-5-il)-7-(1-hi droxipropano-2-il)-1-(1h-indol-3-il)-6,7-dihidro-3h-oxazol[3,4-a] pirazina-5,8-diona y su uso como antitumoral y inhibidor de la enzima fosfodiesterasa. |
CA3144770A CA3144770A1 (en) | 2019-07-15 | 2020-07-14 | Stereoisomers of the compound 3-(benzo[d][1,3]dioxol-5-yl)-7-(1-hydroxypropan-2-yl)-1-(1h-indol-3-yl)-6,7-dihydro-3h-oxazol[3,4-a]pyrazine-5,8-dione and use thereof as an antitumor agent and phosphodiesterase enzyme inhibitor |
JP2022502020A JP2022540866A (ja) | 2019-07-15 | 2020-07-14 | 3-(ベンゾ[d][1,3]ジオキサゾール-5-イル)-7-(1-ヒドロキシプロパン-2-イル)-1-(1H-インドール-3-イル)-6,7-ジヒドロ-3H-オキサゾール[3,4-a]ピラジン-5,8-ジオン化合物の立体異性体およびその抗腫瘍剤およびホスホジエステラーゼ酵素阻害剤としての使用 |
CN202080051067.1A CN114158266A (zh) | 2019-07-15 | 2020-07-14 | 化合物3-(苯并[d][1,3]二氧杂环戊烯-5-基)-7-(1-羟基丙-2-基)-1-(1H-吲哚-3-基)-6,7-二氢-3H-噁唑并[3,4-a]吡嗪-5,8-二酮的立体异构体及其作为抗肿瘤剂和磷酸二酯酶抑制剂的用途 |
EP20839690.3A EP4001282A4 (en) | 2019-07-15 | 2020-07-14 | STEREOISOMERS OF THE COMPOUND 3-(BENZO[D][1,3]DIOXOL-5-YL)-7-(1-HYDROXYPROPAN-3-YL)-1-(1H-INDOL-3-YL)-6,7- DIHYDRO-3H-OXAZOLE[3,4-A]PYRAZINE-5,8-DIONE AND USE THEREOF AS AN ANTI-TUMORROW AGENT AND PHOSPHODIESTERASE ENZYME INHIBITOR |
US17/626,635 US20220296590A1 (en) | 2019-07-15 | 2020-07-14 | Stereoisomers of the compound 3-(benzo[d][1,3]dioxol-5-yl)-7-(1-hydroxypropan-2-yl)-1-(1h-indol-3-yl)-6,7-dihydro-3h-oxazol[3,4-a]pyrazine-5,8-dione and use thereof as an antitumor agent and phosphodiesterase enzyme inhibitor |
IL288971A IL288971A (en) | 2019-07-15 | 2021-12-13 | Spatial isomers of the compound 3-(benzo[d][1,3]dioxol-5-yl)-7-(1-hydroxypropan-2-yl)-1-(h1-indol-3-yl)-7,6 -dihydro-h3-oxazolo[4,3-a]pyrazine-8,5-dione and its use as an antitumor agent and as a phosphodiesterase enzyme inhibitor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962874321P | 2019-07-15 | 2019-07-15 | |
US62/874,321 | 2019-07-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021007636A1 true WO2021007636A1 (pt) | 2021-01-21 |
Family
ID=74209603
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/BR2020/050259 WO2021007636A1 (pt) | 2019-07-15 | 2020-07-14 | Estereoisômeros do composto 3-(benzo[d][1,3]dioxol-5-il)-7-(1-hidroxipropan-2-il)-1-(1 h-indol-3-il)-6,7-dihidro-3 h-oxazol[3,4-a]pirazina-5,8-diona e seu uso como antitumoral e inibidor da enzima fosfodiesterase |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220296590A1 (pt) |
EP (1) | EP4001282A4 (pt) |
JP (1) | JP2022540866A (pt) |
KR (1) | KR20220035048A (pt) |
CN (1) | CN114158266A (pt) |
AR (1) | AR119407A1 (pt) |
BR (1) | BR112021024894A2 (pt) |
CA (1) | CA3144770A1 (pt) |
IL (1) | IL288971A (pt) |
MX (1) | MX2021015425A (pt) |
WO (1) | WO2021007636A1 (pt) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3635178A (en) | 1970-04-17 | 1972-01-18 | Home Curtain Corp | Machine for making shirred curtains |
US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
US5859006A (en) | 1994-01-21 | 1999-01-12 | Icos Corporation | Tetracyclic derivatives; process of preparation and use |
WO1999011279A1 (en) | 1997-09-04 | 1999-03-11 | Rexall Sundown, Inc. | Composition and method for the treatment of benign prostatic hyperplasia and prostatitis |
WO2012019254A1 (en) * | 2010-08-13 | 2012-02-16 | Biolab Sanus Farmacêutica Ltda. | Derivatives of 6, 7-dihydro-3h-oxazolo [3, 4-a] pyrazine-5, 8- dione |
US20120252816A1 (en) * | 2011-03-28 | 2012-10-04 | Chen Zhe-Sheng | Use of phosphodiesterase inhibitors for treating multidrug resistance |
WO2015123748A1 (pt) * | 2014-02-24 | 2015-08-27 | Biolab Sanus Farmaceutica Ltda | "NOVOS COMPOSTOS DERIVADOS DE 6,7-DIHIDRO-3H-OXAZOLO [3,4-a] PIRAZINA-5,8-DIONA " |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019130052A1 (en) * | 2017-12-26 | 2019-07-04 | Ftf Pharma Private Limited | Liquid oral formulations for pde v inhibitors |
-
2020
- 2020-07-14 WO PCT/BR2020/050259 patent/WO2021007636A1/pt unknown
- 2020-07-14 BR BR112021024894A patent/BR112021024894A2/pt unknown
- 2020-07-14 CN CN202080051067.1A patent/CN114158266A/zh active Pending
- 2020-07-14 JP JP2022502020A patent/JP2022540866A/ja active Pending
- 2020-07-14 MX MX2021015425A patent/MX2021015425A/es unknown
- 2020-07-14 US US17/626,635 patent/US20220296590A1/en active Pending
- 2020-07-14 KR KR1020217043172A patent/KR20220035048A/ko unknown
- 2020-07-14 CA CA3144770A patent/CA3144770A1/en active Pending
- 2020-07-14 EP EP20839690.3A patent/EP4001282A4/en active Pending
- 2020-07-15 AR ARP200101981A patent/AR119407A1/es unknown
-
2021
- 2021-12-13 IL IL288971A patent/IL288971A/en unknown
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3635178A (en) | 1970-04-17 | 1972-01-18 | Home Curtain Corp | Machine for making shirred curtains |
US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
US5859006A (en) | 1994-01-21 | 1999-01-12 | Icos Corporation | Tetracyclic derivatives; process of preparation and use |
WO1999011279A1 (en) | 1997-09-04 | 1999-03-11 | Rexall Sundown, Inc. | Composition and method for the treatment of benign prostatic hyperplasia and prostatitis |
WO2012019254A1 (en) * | 2010-08-13 | 2012-02-16 | Biolab Sanus Farmacêutica Ltda. | Derivatives of 6, 7-dihydro-3h-oxazolo [3, 4-a] pyrazine-5, 8- dione |
US8338432B2 (en) | 2010-08-13 | 2012-12-25 | Biolab Sanus Farmaceutica Ltda. | Derivatives of 6,7-dihydro-3H-oxazolo[3,4-a]pyrazine-5,9-dione as PDE-5 inhibitors |
US20120252816A1 (en) * | 2011-03-28 | 2012-10-04 | Chen Zhe-Sheng | Use of phosphodiesterase inhibitors for treating multidrug resistance |
WO2015123748A1 (pt) * | 2014-02-24 | 2015-08-27 | Biolab Sanus Farmaceutica Ltda | "NOVOS COMPOSTOS DERIVADOS DE 6,7-DIHIDRO-3H-OXAZOLO [3,4-a] PIRAZINA-5,8-DIONA " |
US9359378B2 (en) | 2014-02-24 | 2016-06-07 | Biolab Sanus Farmaceutica Ltda. | Substituted oxazolo[3,4-a]pyrazines as pharmaceutcals |
Non-Patent Citations (4)
Title |
---|
JOHNSEN NIELS, LIMIN MA, ASIM ABDEL-MAGEED: "Tadalafil Inhibits Prosate Cancer Cell Growth in a Dose-Dependent Manner", THE JOURNAL OF UROLOGY, 17 May 2011 (2011-05-17), XP055783633 * |
KORKES, F. ET AL., J BRAS NEFROL., vol. 31, no. 1, 2009, pages 55 |
See also references of EP4001282A4 |
VAN DER WERF ET AL., BJU INTERNATIONAL, vol. 90, 2002, pages 588 |
Also Published As
Publication number | Publication date |
---|---|
BR112021024894A2 (pt) | 2022-01-25 |
AR119407A1 (es) | 2021-12-15 |
IL288971A (en) | 2022-02-01 |
CN114158266A (zh) | 2022-03-08 |
US20220296590A1 (en) | 2022-09-22 |
JP2022540866A (ja) | 2022-09-20 |
EP4001282A4 (en) | 2023-07-19 |
CA3144770A1 (en) | 2021-01-21 |
EP4001282A1 (en) | 2022-05-25 |
MX2021015425A (es) | 2022-02-21 |
KR20220035048A (ko) | 2022-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1746097B1 (en) | 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them | |
ES2278956T3 (es) | Derivados de carbolina como inhibidores de fosfodiesterasa 5 (pde5) para el tratamiento de enfermedades cardiovasculares y de la disfuncion erectil. | |
PT1888578E (pt) | Imidazoquinolinas como inibidores de quinase lipídica | |
CN102762563A (zh) | 作为nadph氧化酶抑制剂的吡唑并哌啶衍生物 | |
BR112021008323A2 (pt) | sulfonamida substituída com trifluorometil como inibidor seletivo de bcl-2 | |
HUE024989T2 (en) | Azaindole derivatives as ABI and SRC protein kinase inhibitors | |
WO2013178021A1 (zh) | 吡咯并[2,1—f][1,2,4]三嗪衍生物及其抗肿瘤用途 | |
US20060264439A1 (en) | Inhibitors of polo-like kinase-1 | |
JP2013530130A (ja) | ヘテロアリール(アルキル)ジチオカルバメート化合物、その調製方法及び使用 | |
CN114195814B (zh) | 羟基萘酮-苯硼酸类化合物、制备方法和用途 | |
JP5889987B2 (ja) | ポリアミンの新規な蛍光誘導体、その製造方法、および癌性腫瘍の治療における診断手段としてのその使用 | |
CN114276333B (zh) | 二氢喹喔啉类溴结构域二价抑制剂 | |
EP1556382A1 (fr) | Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique. | |
CN113045559B (zh) | 一种二芳基脲类PI3Kα/mTOR双靶点抑制剂及其药物组合物和应用 | |
EP3302060B1 (en) | Pyrazolo[4,3-c]quinoline derivatives for inhibition of -glucuronidase | |
WO2021007636A1 (pt) | Estereoisômeros do composto 3-(benzo[d][1,3]dioxol-5-il)-7-(1-hidroxipropan-2-il)-1-(1 h-indol-3-il)-6,7-dihidro-3 h-oxazol[3,4-a]pirazina-5,8-diona e seu uso como antitumoral e inibidor da enzima fosfodiesterase | |
CN110183503B (zh) | 磺酰氮杂螺癸二烯酮类化合物及其用途 | |
BR112019014528A2 (pt) | Compostos e seu uso no tratamento da esquistossomose | |
CN103980252A (zh) | 制备含1,2,4-三氮唑的吡唑类席夫碱治疗肿瘤的药物 | |
CN108456214B (zh) | 含噁唑或咪唑结构的喹唑啉类化合物及其应用 | |
KR101571915B1 (ko) | Hdac 저해제로서의 술포닐피롤의 신규 제조 방법 | |
CN109134433B (zh) | 一种抑制rock的化合物及其应用 | |
US20200246328A1 (en) | Method for producing benzazoloquinolium (BQs) salts and using the biological activity of the composition | |
CN114736203A (zh) | 作为bcl-2抑制剂的杂环化合物 | |
KR100468352B1 (ko) | 신규 피라졸로피리미딘계 유도체, 그의 제조방법 및 이를 유효성분으로 하는 약학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20839690 Country of ref document: EP Kind code of ref document: A1 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021024894 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 3144770 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022502020 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 112021024894 Country of ref document: BR Kind code of ref document: A2 Effective date: 20211209 |
|
ENP | Entry into the national phase |
Ref document number: 2020839690 Country of ref document: EP Effective date: 20220215 |